NRX Pharmaceuticals (NRXP) Current Deferred Revenue (2021 - 2022)
NRX Pharmaceuticals' (NRXP) quarterly Current Deferred Revenue came in at $56000.0 in Q3 2022, down 95.56% year-on-year from $1.3 million in Q3 2021, and up 194.74% on a QoQ basis from $19000.0 in Q2 2022.
NRX Pharmaceuticals (NRXP) Current Deferred Revenue (2021 - 2022) Analysis & Trends
NRX Pharmaceuticals (NRXP) has 2 years of Current Deferred Revenue data on file, last reported at $56000.0 in Q3 2022.
- On a quarterly basis, Current Deferred Revenue fell 95.56% year-over-year to $56000.0 in Q3 2022; TTM through Sep 2022 was $56000.0, a 95.56% decrease from a year earlier, with the FY2021 full-year figure at $292000.0, changed N/A from the prior year.
- Current Deferred Revenue for Q3 2022 stood at $56000.0, up from $19000.0 in the prior quarter.
- Over the last five years, Current Deferred Revenue for NRXP reached as high as $22.8 million in Q2 2021 and fell as low as $19000.0 in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | NRX Pharmaceuticals | 137.57 Mn | 130.87 Mn | 437,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 56,000.00 |
| Jun 30, 2022 | 19,000.00 |
| Mar 31, 2022 | 135,000.00 |
| Dec 31, 2021 | 292,000.00 |
| Sep 30, 2021 | 1.26 Mn |
| Jun 30, 2021 | 22.85 Mn |